Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intrathecal RO7234292 (RG6042) for Huntington's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• RG6042 (RG6042)
• RO7234292 (RO7234292)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Huntingtons Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-11-07